Fibrosis is defined as an excessive deposition of connective tissue components and can
affect virtually every organ system, including the skin, lungs, liver and kidney. Fibrotic tissue …

Structural changes involving tissue remodelling and fibrosis are major features of many
pulmonary diseases, including asthma, chronic obstructive pulmonary disease (COPD) and …

Idiopathic pulmonary fibrosis (IPF) is a progressive, and ultimately fatal, chronic interstitial
lung disease characterized by enhanced extracellular matrix deposition. Repetitive alveolar …

Idiopathic pulmonary fibrosis (IPF) is a progressive disease with a dismal prognosis. The
average life expectancy of untreated patients with IPF is only 3 to 4 years. Decline in forced …

Abstract Background Systemic sclerosis (SSc) is a rare connective tissue disease with a
heterogeneous clinical course. Interstitial lung disease (ILD) is a common manifestation of …

Idiopathic pulmonary fibrosis (IPF) is a chronic interstitial lung disease characterized by an
abnormal reepithelialisation, an excessive tissue remodelling and a progressive fibrosis …

Pirfenidone (PFD) is a pharmacological compound with therapeutic efficacy in idiopathic
pulmonary fibrosis. It has been chiefly characterized as an antifibrotic agent, although it was …

Rationale: Nintedanib and pirfenidone slow the progression of idiopathic pulmonary fibrosis
(IPF), but the disease continues to progress. More data are needed on the safety and …

Pulmonary fibrosis, particularly idiopathic pulmonary fibrosis, represents a chronic and
progressive disease with high mortality and limited therapeutic options. Excessive …

Myofibroblasts are characterized by their expression of α-smooth muscle actin, their
enhanced contractility when compared to normal fibroblasts and their increased synthetic …